YUCAIPA, Calif., Oct. 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.


Related Quotes
Symbol Price Change
IGNT.PK 0.0033 -0.0001


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.



In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.



In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.



"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

ignt started to move friday and with news that came out friday and today with a grooss profit increase and 63% gross margin in sales that should get this moving fast. ignt is a good quick investment , should get hot through the week with more poss news at close today

YUCAIPA, Calif., Nov 4, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview Nasal Cannulas in value of $100,000.
A growing elderly population, increase in home oxygen therapy and surgeries, and an increase in Chronic Obstructive Pulmonary Diseases in the USA has resulted in an increase of buyers for Ingen's new Oxyview Nasal Cannula. The company now provides 8 different models of the Oxyview and Oxyview Nasal Cannula. The cannulas are designed for Adults, Pediatrics and Infants, and include 0-6 liters/minute and a low-flow 0-3 liters/minute unit that is either reusable or comes attached to a high quality 7' latex free oxygen tube with a curved soft-tip nasal cannula. The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow rate readings for the patient and caregiver.

The company also received very good news today from the COPD Foundation. The November issue of COPD Digest has been printed and shipped and is receiving an excellent response at the American College of Chest Physician's Annual 2009 conference in San Diego, CHEST 2009. Ingen has a full-page color ad in this edition of the COPD Digest and telephone orders and PayPal orders have increased this week.

"We are seeing a strong increase in revenues, and expect this trend to continue over the next several years. Our accountants and auditors are diligently working on completion of the SEC filings, specifically the 10-KSB. We anticipate filing a revised annual and quarterly report on the OTC Pink Sheets later next week. The company is progressing forward very nicely at this time and we will continue to make public announcements as each event occurs," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board

IGNT
all the charts are possitive , volume is up and still moving
i feel like that ignt could gain speed n start to make a nice push

new news!! looks hot IMO!!

Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase
CEO Live Radio Broadcast Talks About These New Markets

Press Release
Source: Ingen Technologies, Inc.
On 4:15 pm EST, Friday November 20, 2009


YUCAIPA, Calif., Nov. 20, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.


Related Quotes
Symbol Price Change
IGNT.PK 0.0029 +0.0001


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.



The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 - 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.



"Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies," stated Scott Sand, Chief Executive Officer and Chairman of the Board.

--------------------------------------------------------------------------------

IGNT - Tradeing with high volume today!!!
This is one to watch!!! RSI LINE approaching Bullish - Mac D running even

This leading medical device manufacture that is focused on the $4B respiratory market with their oxyview products for the growing ageing population & emerging markets for home.

A growing elderly popuulation increase in home oxygen therapy & surgeries, & an increase in chronic obstructive pulmonary dieseases in the USA has resulted in an increase of buyers for Ingen’s new Oxyview Nasal Cannula. Now provides models for adults, pediatrics & infants.

The Oxyview Nasal Cannula is the only oxygen cannula in the world with a flow meter built-in that provides extremely accurate flow readings.

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

IGNT 0.0027 0.0005

Today 5d 1m 3m 1y 5y 10y



Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Jan. 6, 2010 (GlobeNewswire) --
YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.










A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6961

The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.

This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.

"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

www.oxyviewnasalcannula.com

www.ingen-tech.com

About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

CONTACT: Ingen Technologies, Inc.
Jeff Morgan
909-790-7180
www.info@ingen-tech.com






Source: GlobeNewswire (January 6, 2010 - 1:36 PM EST)

News by QuoteMedia
www.quotemedia.com

IGNT news was awesome. They signed a 3 year supply aggrement with Amsino. With these two comapnies working together will reduce the manufacturing cost by 40%. As I am watching this stock move today I expect a great run today and the rest of the week. Charts show the stock is on a uptrend and price has broken through the 8,20,50 day moving avgs. Stock is now bullish @56.69 and heading north to power. This nis the perfect time to load up on this one and swing trade this one!!!!

Ingen Introduces Oxyview Products at ATS
Effective Advertising and Product Branding Scheduled for 2010


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0023 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Thursday January 14, 2010, 8:15 am

YUCAIPA, Calif., Jan. 14, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced the introduction of their Oxyview product line at the 2010 ATS International Conference on May 14-19, 2010 in New Orleans, Louisiana.



The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine.



The company will reach 13,000 pulmonologists through the advertising in Medco Forum's ATS issue that is scheduled to be released on May 1, 2010. Medco Forum will also host the Oxyview advertising on their website.



The company now advertises in several major publications, inclusive of COPD Digest, Today's Senior Magazine and Medco Forum.



Throughout 2009, Ingen showcased their newest medical respiratory equipment at several conventions, including the MEDICA convention in Germany and the American Association of Respiratory Care (AARC) in San Antonio, Texas. These showings captured the attention of many distributors who were interested in Oxyview, taking Ingen a step closer to achieving international distribution and a growing presence in the hospital and therapy markets.



As the number of respiratory diseases continue to increase, so too does the number of patients requiring oxygen support. That's why Ingen expects to see more demand for the Oxyview Nasal Cannula and the Oxyview Pulse Oximeter in 2010 and the coming years. The company expects to acquire more distributors in the United States and the developing markets of Asia, Canada, Australia and Europe.



http://www.thoracic.org/sections/meetin ... ence/2010/



http://www.medcoforum.com/



http://www.ingen-tech.com/

IGNT Off to a slow start this morning. Stock is bearish right now but with this news that came out on the stock this morning I expect this stock to bounce back this afternoon and tmw. I also think today the stock will push through .25 and .26 today and see more apprecation tmw. I personally am playing this as a swing trade. Remember to do ur own research and this is strictly my opinion